SCHEMBL31358837

SCHEMBL31358837

O=C1C(=Cc2ccc(-c3ccc(F)cc3)o2)C(=O)c2ccccc21

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 8/20 0.69
▸ KMT2A Q03164 8/20 0.69
▸ AKT1 P31749 1/20 0.58
▸ ALDH1A1 P00352 5/20 0.55
▸ KDM4E B2RXH2 5/20 0.55
▸ LMNA P02545 2/20 0.55
▸ POLB P06746 7/20 0.55
▸ MAPT P10636 6/20 0.55
▸ L3MBTL1 Q9Y468 5/20 0.55
▸ PKM P14618 4/20 0.55
▸ TDP1 Q9NUW8 3/20 0.55
▸ CTDSP1 Q9GZU7 2/20 0.55
▸ RECQL P46063 2/20 0.55
▸ HPGD P15428 2/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ MCL1 Q07820 1/20 0.55
▸ IGF1R P08069 1/20 0.51
▸ PPM1G O15355 1/20 0.49
▸ PTPN1 P18031 1/20 0.49
▸ PTPN7 P35236 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358723 0.88 MEN1 (0.72) MEN1KMT2AAKT1ALDH1A1KDM4E
SCHEMBL31358681 0.85 MEN1 (0.69) MEN1KMT2AAKT1ALDH1A1KDM4E
SCHEMBL31358759 0.85 MEN1 (0.73) MEN1KMT2AAKT1ALDH1A1KDM4E
SCHEMBL31358866 0.85 KMT2A (0.69) MEN1KMT2AAKT1ALDH1A1KDM4E
SCHEMBL13479578 0.85 MEN1 (0.69) MEN1KMT2AAKT1ALDH1A1KDM4E
SCHEMBL31358773 0.85 MEN1 (0.69) MEN1KMT2AAKT1ALDH1A1KDM4E
SCHEMBL31358726 0.85 AKT1 (0.58) MEN1KMT2AAKT1ALDH1A1KDM4E
SCHEMBL31358667 0.82 POLB (0.58) MEN1KMT2AAKT1ALDH1A1KDM4E
SCHEMBL31358724 0.82 PIK3CG (0.56) MEN1KMT2AAKT1ALDH1A1KDM4E
SCHEMBL31358826 0.82 KMT2A (0.64) MEN1KMT2AAKT1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 MEN1 2467/4885KMT2A 1043/4885AKT1 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback